Movement Alert｜Ascendis Pharma A/S Intraday Rise 4.14% in Regular Trading, Price Target Increase and Q3 Results Beat Support Shares

Market Focus11-14 02:11

On November 14, Ascendis Pharma A/S rose 4.14% in Regular Trading, trading at $278.14 per share, with turnover of $84.0114 million.

The move appears supported by a fresh analyst price target increase alongside third-quarter results that exceeded market expectations.

Most recently, Wedbush raised its price target on Ascendis Pharma A/S to $346 from $327 while maintaining an outperform rating. This followed the company’s third-quarter report released on November 12, which showed revenue of 369.7 million euros, above the 361.4 million euros expected by analysts, and adjusted EPS of $1.97, well above the $1.13 consensus. Product revenue reached 366 million euros, including 291 million euros from YORVIPATH, while management said full-year operating cash flow is expected to be at least 600 million euros.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment